Dashboard
1
Strong Long Term Fundamental Strength with an average Return on Equity (ROE) of 12.73%
- Healthy long term growth as Net Sales has grown by an annual rate of 10.38% and Operating profit at 10.94%
- Company has very low debt and has enough cash to service the debt requirements
2
With ROE of 12.52%, it has a expensive valuation with a 1.80 Price to Book Value
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-2.82%
0%
-2.82%
6 Months
21.22%
0%
21.22%
1 Year
-11.17%
0%
-11.17%
2 Years
-16.98%
0%
-16.98%
3 Years
-43.89%
0%
-43.89%
4 Years
-27.29%
0%
-27.29%
5 Years
-20.19%
0%
-20.19%
Rohto Pharmaceutical Co., Ltd. for the last several years.
Risk Adjusted Returns v/s 
News

Rohto Pharmaceutical Hits Day Low Amid Price Pressure, Shares at JPY 2,356.00
Rohto Pharmaceutical Co., Ltd. saw its stock decline significantly, contrasting with the broader market's performance. Over the past year, the company has faced substantial challenges, with notable decreases in stock value. Despite this, Rohto maintains a solid return on equity and a favorable debt-to-equity ratio.
Read More Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
10.38%
EBIT Growth (5y)
10.94%
EBIT to Interest (avg)
100.00
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
-0.10
Sales to Capital Employed (avg)
1.02
Tax Ratio
26.88%
Dividend Payout Ratio
26.45%
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
21.17%
ROE (avg)
12.73%
Valuation key factors
Factor
Value
P/E Ratio
14
Industry P/E
Price to Book Value
1.80
EV to EBIT
11.50
EV to EBITDA
8.57
EV to Capital Employed
1.90
EV to Sales
1.43
PEG Ratio
10.29
Dividend Yield
0.03%
ROCE (Latest)
16.49%
ROE (Latest)
12.52%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bullish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bullish
Bearish
Moving Averages
Bullish (Daily)
KST
Mildly Bearish
Bearish
Dow Theory
Mildly Bearish
No Trend
OBV
Mildly Bullish
No Trend
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ
Jun'25
Mar'25
Change(%)
Net Sales
81,964.00
82,730.00
-0.93%
Operating Profit (PBDIT) excl Other Income
15,712.00
11,194.00
40.36%
Interest
316.00
385.00
-17.92%
Exceptional Items
-1,058.00
-1,218.00
13.14%
Consolidate Net Profit
12,052.00
6,340.00
90.09%
Operating Profit Margin (Excl OI)
141.90%
79.20%
6.27%
USD in Million.
Net Sales
QoQ Growth in quarter ended Jun 2025 is -0.93% vs -4.70% in Mar 2025
Consolidated Net Profit
QoQ Growth in quarter ended Jun 2025 is 90.09% vs -46.28% in Mar 2025
Annual Results Snapshot (Consolidated) - Mar'25
Mar'25
Mar'24
Change(%)
Net Sales
308,625.00
270,840.00
13.95%
Operating Profit (PBDIT) excl Other Income
51,608.00
48,854.00
5.64%
Interest
949.00
196.00
384.18%
Exceptional Items
-2,068.00
-916.00
-125.76%
Consolidate Net Profit
30,951.00
31,394.00
-1.41%
Operating Profit Margin (Excl OI)
124.60%
148.30%
-2.37%
USD in Million.
Net Sales
YoY Growth in year ended Mar 2025 is 13.95% vs 13.48% in Mar 2024
Consolidated Net Profit
YoY Growth in year ended Mar 2025 is -1.41% vs 18.79% in Mar 2024
About Rohto Pharmaceutical Co., Ltd. 
Rohto Pharmaceutical Co., Ltd.
FMCG
No Details Available.
Company Coordinates 
No Company Details Available






